
Caleb Miller
1.5K posts

Caleb Miller
@cmiller__
Graphics programmer and general UI guy. Addicted to JavaScript and caffeine. Pretty good at plugging in USB Type-A cables.




Created a flag on the moon based with hyper-realistic physics with @v0: v0-moon-flag.vercel.app. The flag is simulated as a grid of particles connected by springs (cloth simulation). It's influenced by gravity, wind, air resistance. The initial approach v0 one-shotted was quite simplistic, but giving it references to more sophisticated approaches in C++ and Rust quickly improved it. It was mind-blowing it to see it deeply understand the physics and port new ideas across languages. It simulated a real sun for lighting, and procedurally generated moon-like terrain with craters. I found a sick free texture on Reddit that I uploaded and it layered on top. Another epic moment was watching it improve performance. It seamlessly moved the physics simulation to a Web Worker. (Kinda cool to see given we just improved support for them in Turbopack 😉)












LLM explaining why it added yet another branch in perf critical inner loop: > "defensive fallback for callers that might render an unsynchronized scene" There's no such thing as "unsynchronized scene".





A single dose of a new cancer drug made a brain tumor almost disappear – in just five days. Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma, one of the most aggressive brain cancers known. The therapy, called CARv3-TEAM-E, was developed to overcome a major hurdle in treating solid tumors: their ability to hide from the immune system. The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma. Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness. The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.





